GlaxoSmithKline has entered into a deal to buy Pliva's state-of-the-art R&D facility Pliva-Istrazivacki Institut. Having recently reported an annual profit of GBP6.7 billion, Europe's biggest drugmaker will now hope to improve this financial performance by moving its research activities to lower-cost emerging markets.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions